TMED2 promotes epithelial ovarian cancer growth.

about

TMED2 promotes epithelial ovarian cancer growth.

Item

http://www.wikidata.org/entity/Q47145289

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

TMED2 promotes epithelial ovarian cancer growth.

@en

TMED2 promotes epithelial ovarian cancer growth.

@nl

type

Item

label

TMED2 promotes epithelial ovarian cancer growth.

@en

TMED2 promotes epithelial ovarian cancer growth.

@nl

prefLabel

TMED2 promotes epithelial ovarian cancer growth.

@en

TMED2 promotes epithelial ovarian cancer growth.

@nl

P1476

TMED2 promotes epithelial ovarian cancer growth.

@en

P2093

Cai Ye-Ping

http://www.w3.org/2001/XMLSchema#string

Chen Chun-Lin

http://www.w3.org/2001/XMLSchema#string

Chen Yong-Ning

http://www.w3.org/2001/XMLSchema#string

Gong Shi-Peng

http://www.w3.org/2001/XMLSchema#string

Meng Fan-Liang

http://www.w3.org/2001/XMLSchema#string

Wu Huan

http://www.w3.org/2001/XMLSchema#string

Zhang Guang-Ping

http://www.w3.org/2001/XMLSchema#string

Zhang Ya-Di

http://www.w3.org/2001/XMLSchema#string

P2860

Selective export of human GPI-anchored proteins from the endoplasmic reticulum

Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody

The trafficking protein Tmed2/p24beta(1) is required for morphogenesis of the mouse embryo and placenta

starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data.

Discovery of novel cell proliferation-enhancing gene by random siRNA library based combinatorial screening.

Long non-coding RNA PTENP1 functions as a ceRNA to modulate PTEN level by decoying miR-106b and miR-93 in gastric cancer

Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.

Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial.

TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.

P304

94151-94165

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.21593

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29212217

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer

P932

5706863

http://www.w3.org/2001/XMLSchema#string